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We have evaluated the potential of flow injection chemical reaction interface isotope-ratio
mass spectrometry to replace radioactive labeling techniques in material balance studies. A
sample is flow injected and transmitted through a desolvation system followed by combustion
to form 13CO2 with a microwave-powered chemical reaction interface. We can detect trace
amounts of a 13C-labeled drug (39-azido-39-deoxythymidine, AZT) in urine or feces. Our ability
to quantify less than 100 ng/mL of excess 13C (;1 mg/mL of 13C-labeled AZT) from a sample
equivalent to 10 mL of urine is superior to previous detection limits for 13C in urine that use
off-line combustion methods. Parallel studies using 14C-labeled AZT showed that our stable
isotope method provides comparable percent excretion data for urine and feces. These results
support previous findings that mass balance studies could be carried out with isotope-ratio
mass spectrometer, here using doses as low as 1–2 mg/kg. (J Am Soc Mass Spectrom 1999,
10, 153–158) © 1999 American Society for Mass Spectrometry
Despite the increasing emphasis on the use ofstable isotopes, one necessary component ofpreclinical and clinical drug testing that contin-
ues to rely on radioisotope methodology is the material
balance study. In such a study, one needs to know the
percent of a drug that is found in a given biological
fluid or tissue, independent of whether the drug exists
in its original form or as any metabolite. This need has
dictated the use of radioisotopes that have both low
limits of detection and compound-independent sensi-
tivity factors. Over the years, some attempts have been
made to use stable isotope methodology and an isotope-
ratio mass spectrometer (IRMS), but these preliminary
studies do not appear to have been followed up by the
pharmaceutical industry.
The first study of this type was conducted by von
Unruh et al. [1]. They used the conventional method
where a sample of urine was combusted and the
resulting CO2 was admitted into an IRMS. Their studies
of variability in the baseline for the 13C/12C ratio from
urine showed only small [SD d13CPDB . 1‰ (this
terminology is explained in the Methods section)] fluc-
tuations over a 10 day period. This was reassuring
because variations in diet will be reflected as variations
in the baseline and could significantly limit the utility of
stable isotope methods where differences below 1‰
can be measured. Knowing that the reproducibility of
13C ratios of urine was good enough to permit this type
of experiment, one subject was given a 0.32 mg dose of
13C-labeled aspirin along with a 320 mg dose of unla-
beled aspirin. The urine results showed a d13C value
2.8‰ above the control 13C/12C ratio using a 1% aliquot
(8–16 mL) of a 24 h human urine sample. This elevated
ratio converts to detecting an 83 6 52% excretion of the
administered 13C aspirin dose into urine.
Nakagawa et al. [2] measured d13C and d15N in rat
urine, feces, liver, and hair, again by combustion and
measurement of the resulting CO2 and N2 by IRMS.
Like von Unruh et al. [1], they found low baseline
variations in both d13C and d15N values for blood, urine,
feces, liver, and hair (SE # 0.5%) and reported a
material balance study with about 610‰ reproducibil-
ity following a 40 mg/kg dose of 13C, 15N2-antipyrine.
Browne and co-workers [3] also examined this ques-
tion, but using a different experimental approach. Here,
a gas chromatograph was used to time focus the CO2
generated from off-line combustion, and to separate
CO2 from N2 and H2O. For untreated urine they could
detect ;4 mg/mL of a 13C2-labeled drug. When high
performance liquid chromatography (HPLC) was used
to capture the one peak of interest that contained their
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labeled drug, their sensitivity improved to 0.015 mg/
mL.
We approached this problem by using liquid flow
injection to examine the potential of stable isotopes in
material balance studies. The system used the chemical
reaction interface mass spectrometry (CRIMS) tech-
nique that we recently adapted to an IRMS [4]. Follow-
ing flow injection, CO2 will be produced and transmit-
ted to the IRMS in a steady stream of helium for the
duration of the injection period. Flow injection provides
efficient sample utilization and flexibility in the size of
the sample analyzed. Our preliminary work with amin-
opyrine [5] spiked into human urine generated a non-
specific extraction scheme that contained all the organic
carbon in urine and provided detection limits below
0.05 mg/mL of excess 13C. The present study examines
this approach in an in vivo experiment with 39-azido-39-
deoxythymidine (AZT) in rats.
Materials and Methods
Chemicals
Methanol and water with less than 0.1 ppm evaporation
residue were obtained from EM Science (Gibbstown,
NJ). AZT, methyl-13C (99% labeled) was obtained from
Cambridge Isotope Laboratories (Andover, MA) and
AZT-2-14C ($98%) was obtained from Moravek Bio-
chemicals, Inc. (Brea, CA). 29-Deoxycytidine 59-mono-
phosphate (dCMP $98%) was obtained from Sigma
Chemical Co. (St. Louis, MI). Isopropanol and potas-
sium carbonate A.C.S. grade were obtained from Fisher
Scientific (Pittsburgh, PA).
Instrumentation
The general configuration of the instrument used in
these experiments has been described before [4]. It
consists of a HPLC pumping system coupled to an
IRMS with a unique interface. The mass spectrometer
used was a Finnigan/MAT delta S IRMS (San Jose, CA)
with differential turbopumping and a triple Faraday
cup collector. A Vestec Universal Interface (Vestec Mass
Spectrometry Products, PerSeptive Biosystems, Fra-
mingham, MA) was used to couple the liquid flow from
the HPLC pumps to the CRI [6] before passing into the
IRMS. A split between the CRI and the IRMS that
reduced the incoming gas flow as much as 1:10 was
used. The CRI reactant gas in these experiments was
oxygen [7].
Flow Injection
All experiments were conducted using a pair of Isco
Model 260D syringe pumps (Isco Inc., Lincoln, NE)
coupled with a Gilson Model 811C dynamic mixer. The
mobile phase was 1/1 methanol/water (v/v) at a flow
rate 1 mL/min. All samples were dissolved in 1/1
methanol/water and injected using a Rheodyne 7125
valve. Loop sizes of 20–5000 mL were tested and we
found no significant differences in precision among
them except for the 20 mL loop that led to a higher SD.
With a 100 mL loop, the injected volume was between 25
and 40 mL that provided an m/z 44 signal of about 5 V.
Calculations and Standardization
The 13C/12C ratio is defined as the relative difference
between the sample and a standard, calculated as
d13C~‰! 5 @~RSPL 2 RSTD!/RSTD# z 1000
where RSPL refers to the
17O-corrected 13CO2/
12CO2
ratio of the sample and RSTD refers to the same cor-
rected ratio for the standard, Pee Dee Belemnite (PDB).
(Pee Dee Belemnite no longer exists. Secondary stan-
dards with previous calibrations against PDB are cur-
rently used.) Oxidative CRI chemistry generates NO2
that adds to the m/z 46 signal. Thus, m/z 46 cannot be
used to measure the 12C16O18O content of the sample, a
quantity from which the 17O content is computed and a
correction made to obtain the true 13C16O2 signal at m/z
45. Without this correction, there will be an unknown
error in the accuracy of the d13CPDB values we compute.
With CRIMS, the excess O2 used as the reactant gas,
rather than the trace amounts of oxygen in any analyte,
dictates the isotopic composition of the oxygen in CO2.
While we cannot compute an accurate d13C value from
the observed m/z 44 and 45 channels, the error will be
constant because the isotopic composition of the oxygen
is constant. Changes in the 45/44 ratios between sam-
ples will correctly represent changes in the 13C content.
To be formal, our calculations use the notation PDB*,
where the asterisk denotes the absence of this correction
[4]. In each calculation, the isotope ratio of our standard
(dCMP that we determined had a 13CPDB* of
225.19‰ 6 1.13 via a chain of measurements ulti-
mately linked to PDB) was used as RSTD, and the
isotope ratio of each unknown peak was calculated
from that known value. The integration of the m/z 44
and 45 channels following each injection of either a
sample or the isotope ratio standard dCMP used the
Isodat software with a slope sensitivity of 1 mV/s,
which we found gave the most reproducible values.
Animal Experiments
Three male Sprague–Dawley rats weighing ;300 g
were purchased from Hilltop Lab Animals, Inc. (Scotts-
dale, PA). Animals were housed one per metabolic cage
at room temperature (;25 °C) on a 14 h light cycle. One
batch of Purina lab chow was used throughout a 3 week
control period and during the experiments. The chow
and water were provided ad libitum.
One milligram of 13C-AZT and 1 mCi of 14C-AZT
were dissolved in H2O and injected into each animal
intraperitoneally. The animals were held without food
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for 24 h while collecting their urine and feces. After this
period the urine volumes were measured and 5 mL
were saturated with K2CO3 and extracted with an equal
amount of isopropanol [8]. The fecal samples were
homogenized in a blender with 15 mL of H2O, saturated
with K2CO3 and extracted with 15 mL of isopropanol.
The isopropanol extracts were used to quantify AZT
and its metabolites. The isopropanol extracts were di-
luted ten-fold with methanol/H2O (1/1) and filtered
with a 0.45 mm Cameo Teflon filter (Micron Separations,
Westborough, MA).
Mass Balance using Radioactivity
One microcurie of 14C-AZT was dissolved in 15 mL of
H2O. Spikes of 0, 3, 6, 9, and 12 mL of the stock solution
were added into 7 mL scintillation vials (Fisher brand,
Fisher Scientific, Pittsburgh, PA) containing 4 mL of
Scintiverse BD scintillation counting cocktail (Fisher
Scientific). Ten microliters of the urine or fecal extracts
for rats 1, 2, and 3 were added to scintillation vials with
4 mL of Scintiverse BD. In each case the vials were
vortexed for 10 s. Standard solutions and extracts were
counted in a Beckman LS 6500 Multipurpose Scintilla-
tion Counter (Beckman Instruments, Inc., Columbia,
MD). The counting time for each sample was 1 min and
the 14C disintegrations per minute (D.P.M.) for each
sample was recorded.
Mass Balance using Stable Isotopes
Urine extracts from rats 1, 2, and 3 and a fecal extract
from rat 1 were analyzed with 5–6 replicate injections.
A standard addition graph was generated for each
sample. To accomplish this, we spiked 100 mL of
extracted urine and feces with 100 mL of aqueous
solutions containing various amounts of 13C-AZT and
diluted to 1 mL with mobile phase. Based on the
14C-AZT studies, we knew approximately how much
13C-AZT to expect in each sample. For urine and fecal
extracts from rat 1, 0.50, 1.0, 2.0, 3.0, 4.0, and 5.0 mg of
13C-AZT were added. For urine extracts from rats 2 and
3, 1.0, 3.0, 5.0, 10.0, 15.0, and 20.0 mg of 13C-AZT were
added. The spiked extracts were diluted to 1 mL and
analyzed by flow injection/CRI/IRMS. Their respective
d values were recorded and the 13C-AZT concentration
of the urine and feces were calculated. Between 10 and
50 mL of dCMP (1 mg/mL) were flow injected before
each isopropanol extract to calibrate the isotope ratio
scale. The results are expressed as Dd13C, because the
differences in isotope ratios between unspiked and
spiked urine samples are plotted rather than their
absolute values.
Results and Discussion
To analyze a sample in a mass balance study, it is
imperative that the method is nonselective so that all
labeled species are determined, whatever their chemical
nature. For this reason, radiometric methods have been
standard because they fulfill this criterion. Using
HPLC/CRI/IRMS, the detection of 13C is general, but,
unlike radiometric detection, the matrix can present
problems because of nonvolatile species that are present
at high concentrations. Consequently, the preliminary
phase of our research evaluated how samples were to
be processed. The saturated K2CO3/isopropanol
method was quantitative both for organic carbon from
urine and for the aminopyrine that was our test species.
While the pH of a saturated K2CO3 solution is 11.6, this
extraction process is not limited to basic and neutral
species. In the original work by Horning et al. [8], both
phenobarbital (a weak acid) and caffeine (neutral) were
extracted with 100% efficiency from plasma as mea-
sured with 14C-labeled drugs. That procedure used only
1 mL of isopropanol to extract from 6 mL of diluted
plasma. Here, we used equal amounts of isopropanol
and aqueous sample that should have improved the
extraction for less readily extracted species.
In setting up the Universal Interface (UI), one works
at relatively low (50 °C) temperatures in the countercur-
rent gas diffusion cell to retain marginally volatile
analytes or can elevate the temperature to achieve better
desolvation and prevent condensation. After the initial
years of using the UI, we felt that temperatures greater
than 50 °C markedly improved long-term reliability
and became the standard for our operation. A downside
was that aminopyrine was sufficiently volatile that it
was lost. Volatile drugs and volatile metabolites repre-
sent problems for many HPLC/MS interfaces because
the process of desolvating the liquid phase may also
evaporate analytes. Caffeine is another rather volatile
analyte for which we have noted inconsistent behavior.
Clearly, a HPLC-style interface may be inappropriate
for a mass balance study if there is a chance of volatile
metabolites.
Because of this problem, we switched our experi-
ments to AZT. AZT is one of the few drugs that is
commercially available with both radio- and stable-
isotope carbon labeling. Even so, the 13C label is on a
different position than the 14C label, but the metabolism
of AZT does not appear to involve either of the posi-
tions labeled [9]. A full validation of stable-isotope
methodology for conducting a material balance study
would involve administering both a radio-labeled and
stable-isotope-labeled test molecule and comparing the
elimination of the drug given. With that in mind, the
animals received an injection containing both 14C AZT
and 13C AZT after which the total urinary and fecal
outputs were collected for 24 h and then extracted. The
samples were first examined by scintillation spectrom-
etry so that the fractional excretions could be immedi-
ately determined. Two of the three fecal samples were
below what we anticipated our limit of quantitation
with CRIMS to be: rat 2 was 1.4% and rat 3 was 1.2% of
the administered dose.
To determine the excess 13C for the remaining sam-
ples we used the method of standard additions [10].
155J Am Soc Mass Spectrom 1999, 10, 153–158 DETECTING 13C WITH MASS SPECTROMETRY
Equal volumes (100 mL) of either extracted urine or
feces were spiked with increasing amounts of 13C AZT
and then diluted to 1 mL. Data were plotted and the
linear regression line was drawn. These standard addi-
tion graphs are seen in Figure 1a, b. For rat 1 urine, the
standard addition graph gave r2 5 0.993 with a y 5 0
extrapolation that indicated 58 6 18 (SE) mg of 13C AZT
was excreted or 5.8 6 1.8% of the administered dose.
The calculation was done by multiplying the x intercept
by the total volume of urine, which was 15 mL for rat 1
and rat 2, and 23 mL for rat 3. The graph was inverted
(x9 5 Dd13CPDB* and y9 5 mg/mL
13C AZT) and an-
other regression was done. The purpose of this second
regression was to obtain the relative standard error of
the mg/mL 13C AZT parameter.
The regression of standard additions to rat 2 urine
gave an r2 5 0.998 and the x intercept indicated that
783 6 41 (SE) mg of 13C AZT (or 78 6 4.1% of the
administered dose of 13C AZT) was present. Analysis of
rat 3 urine gave an r2 5 0.999 AZT and a computed
excretion of 807 6 46 (SE) mg 13C AZT (or 81 6 4.6%
13C AZT). The standard additions to the extract of feces
from rat 1 gave r2 5 0.999 and 118 6 6 (SE) mg of 13C
AZT excreted (11.8 6 0.6% of the dose). The percentage
recoveries of animal urine or feces labeled with either
14C-AZT and 13C-AZT are presented and compared in
Table 1. Without conducting these experiments in many
more animals, we cannot figure out whether the 213%
to 12.2% differences between 14C and 13C are system-
atic, analytical, or random. These limited data do not
prove that the CRI/IRMS method is capable of substi-
tuting for radiometric methods, but do show the ability
of our approach to generate data from realistic samples
that track the radiometric data. Experiments to fully
validate a stable isotope method would have to use a
drug with identical positions for the labels and would
Figure 1. Standard additions: The Dd13C-AZTPDB* is plotted against various concentrations (mg/mL)
of 13C-AZT spiked in extracted urine and feces. (a) rat 1: closed circle 5 fecal extract; closed
diamond 5 urine extract. (b) rat 2 5 closed triangle and rat 3 5 closed inverted triangle; urine
extracts. The errors are standard deviations resulting from six replicate injections. The unweighted
linear regression lines are also shown extrapolated to y 5 0.
Table 1. Comparing the percentage recovery AZT as measured
by 14C and 13C
Animal Sample 13C (%) of dose 14C (%) of dose
1 Feces 11.8 11.1
1 Urine 5.8 8.0
2 Urine 78 65
3 Urine 80 68
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have to be repeated a sufficient number of times to
provide statistical assurance of comparability.
The 0–24 h urinary excretion data for rats 2 and 3 are
consistent with published results for AZT in mice, 86%
[9] and rats, 78% [11]. Obviously, the data for rat 1 are
not. We can only assume that the intraperitoneal dose
for rat 1 entered the gut and not the peritoneal space. As
a result, we observed much less drug in urine and
significant amounts in feces, indicative of incomplete
absorption. Ahmed et al. [9] found 4.6% AZT in feces
after i.v. dosing while de Miranda et al. [11] found 20%
in feces after administering the AZT by gavage showing
that higher fecal excretion will occur through partial
absorption. Our material balance for rat 1 is incomplete,
but the imperfect nature of the experiment only allows
speculation about why. Still, this “accident” allowed us
to compare 13C with 14C for lower urinary excretion and
a measurable amount of fecal excretion (12% 13C AZT)
than would have resulted from ideal dosing.
The d13C values from control urines were 229.42 6
0.63, 230.75 6 0.84, 230.34 6 0.73 for rats 1–3, respec-
tively (mean 6 SD, N 5 5) and the fecal control value
was 230.18 6 0.58. From these values, we computed
the limits of quantitation (LOQ) based on the 12SD
values times the total volume of urine divided by the
slope of the regression line. This result was divided by
the total amount of AZT given (1 mg) and then ex-
pressed as a percent. The LOQ from urine for rat 1 was
1.5% of the AZT dose administered; for rat 2, the LOQ
was 2.4% of the AZT administered; and for rat 3 the
LOQ was 2.0% of the dose. For feces, the LOQ in rat 1
was 2.7%. While we did not measure samples of rat
urine containing 13C-labeled AZT enriched at quite
these low levels, it should be recognized that these
estimated LOQs are not extrapolations but effective
interpolations between the readily measured isotope
ratio of control urine and a similar measurement from
an enriched sample.
Our measurements provided better limits of detec-
tion than other work where the conversion of the
sample to CO2 was done with off-line combustion
methods [1, 2]. The only case where a lower percentage
excretion was quantified was in that part of the work by
Browne et al. [3], where they extracted urine with a
selective process and collected a particular HPLC peak
containing the drug molecule of interest. In this way,
they eliminated most of the background from the urine
and could more selectively detect 13C from the targeted
analyte. When actually carrying out a recovery study
for a drug where an unknown extent of metabolism and
range of metabolites existed, the selection of specific
components for IRMS analysis would not be acceptable.
Flow injection analysis was more efficient in both use
of sample and better time management than the other
methods used for material balance studies. In that part
of the report by Brown et al. where they did not use a
selective extraction and HPLC purification process [3],
they introduced the equivalent of 10–20 mL of urine into
their IRMS. We were able to analyze the equivalent of
12.5 mL of urine from our nonselective urine extract
while obtaining better detection limits. The conven-
tional approaches used by von Unruh et al. [1] and
Nakagawa et al. [2] were yet less sensitive. The disad-
vantage of flow injection analysis was the requirement
of nonselective extraction to avoid contaminating the
apparatus with nonvolatile materials. In off-line com-
bustion methods, the nonvolatile materials remain in
the combustion apparatus and only the resulting gases
are transferred to the IRMS.
Conclusions
Stable isotopes (e.g., 13C) are rapidly replacing radioiso-
topes for drug metabolism studies. Using stable iso-
topes has the capacity to reduce: (1) specialized hazards
of working with radioactivity, (2) the highly regulated
and limited use of radioisotopes in humans, (3) the
special problems in manufacturing radiolabeled com-
pounds, and (4) waste disposal of radiolabeled biomed-
ical waste. Our work extends the prospects for conduct-
ing a mass balance study. An extrapolation of our rat
experiments to human studies is illustrative. Our typi-
cal LOQ was about 2% or 20 mg of 13C-AZT in about 17
mL of urine or 1 mg/mL. Twenty micrograms of 13C-
AZT is the same as 1.0 mg of 13C, so our limit for excess
13C is somewhat less than 0.1 mg/mL. We assume a 70
kg person excretes 1200 mL of urine per day, so we
could detect 120 mg of excess 13C. While the calculation
depends on the number of labels and the size of the
drug molecule in which the label is incorporated, we
would predict that 1% of a drug like 13C1-AZT (MW 5
268) given at a dose of 1–2 mg/kg would be quantifi-
able in urine. Extrapolating this level of detection to the
general question of material balance studies suggests
that many drugs of low and intermediate potency could
be analyzed this way. Highly potent drugs would be
given at lower doses than this and our approach to
using stable isotopic labels would not be successful.
We recently showed that HPLC/CRIMS detected 13C
and 15N labels in a drug metabolism study better than a
radioactivity monitor detected 14C [12]. A second favor-
able comparison of 14C and stable isotopes was reported
by Goldthwaite et al. [13]. The present study shows a
different way that new methods of detecting stable
isotopes make it feasible for them to be used in the
pharmaceutical industry for experiments that have pre-
viously demanded the use of radioisotopic labels.
The broad question of how to optimally carry out
mass balance studies with stable isotopes is not an-
swered with this study. While our detection limits are
superior to off-line combustion methods, the possibility
of loss of volatile metabolites in the desolvation process
puts continuous flow methods at a disadvantage. Even
for radioisotopes, one must have concern for volatile
metabolites, such as 14CO2, that would be lost from a
material balance study without special breath trapping.
Further experiments comparing radioisotopes and sta-
ble isotopes are needed to better focus this question.
157J Am Soc Mass Spectrom 1999, 10, 153–158 DETECTING 13C WITH MASS SPECTROMETRY
Acknowledgments
This work was supported by NSF grant no. BIR 9216935 and NIH
grant no. R01-GM36143. A preliminary version of this research
was presented at the 45th ASMS Conference on Mass Spectrom-
etry and Allied Topics, Palm Springs, CA, 1–5 June 1997.
References
1. von Unruh, G. E.; Hauber, D. H.; Schoeller, D. A.; Hayes, J. M.
Biomed. Mass Spectrom. 1974, 1, 345–349.
2. Nakagawa, A.; Kitagawa, A.; Asami, M.; Nakamura, K.;
Schoeller, D. A.; Slater, R.; Minagawa, M.; Kaplan, I. R. Biomed.
Mass Spectrom. 1985, 12, 502–506.
3. Browne, T. R.; Szabo, G. K.; Ajami, A.; Wagner, D. J. Clin.
Pharmacol. 1993, 33, 246–252.
4. Teffera, Y.; Kusmierz, J. J.; Abramson, F. P. Anal. Chem. 1996,
68, 1888–1894.
5. Chen, P.; Teffera, Y.; Abramson, F. P. Proceedings of the 45th
ASMS Conference on Mass Spectrometry Allied Topics, Palm
Springs, CA, 1–5 June 1997; p 707.
6. McLean, M.; Vestal, M. L.; Teffera, Y.; Abramson, F. P.
J. Chromatogr. A 1996, 732, 189–199.
7. Abramson, F. P. Mass Spectrom. Rev. 1994, 13, 341–356.
8. Horning, M. G.; Boucher, E. A.; Stafford, M.; Horning, E. C.
Clin. Chim. Acta 1972, 37, 381–386.
9. Ahmed, A. E.; Jacob, S.; Loh, J.-P.; Samra, S. K.; Nokta, M.;
Pollard, R. B. J. Pharmacol. Exp. Therap. 1991, 257, 479–486.
10. Miller, J. C.; Miller, J. N. Statistics for Analytical Chemistry, 3rd
ed.; Ellis Horwood Limited: West Sussex, 1993; p 117.
11. De Miranda, P.; Burnette, T. C.; Good, S. S. Drug Metab. Dispos.
1990, 18, 315–320.
12. Abramson, F. P.; Teffera, Y.; Kusmierz, J.; Steenwyk, R. C.;
Pearson, P. G. Drug Metab. Dispos. 1996, 24, 697–701.
13. Goldthwaite, C. A. Jr.; Hsieh, F.-Y.; Womble, S. W.; Nobes,
B. J.; Blair, I. A.; Klunk, L. J.; Mayol, R. F. Anal. Chem. 1996, 68,
2996–3001.
158 CHEN ET AL. J Am Soc Mass Spectrom 1999, 10, 153–158
